GlobeNewswire: Immune Pharmaceuticals Inc Contains the last 10 of 280 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T05:30:59ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2016/06/28/851745/0/en/NEW-DATA-SUGGESTS-IMPROVED-TUMOR-RESPONSE-FOR-THE-COMBINATION-OF-AZIXA-AND-IMMUNE-CHECKPOINT-INHIBITORS-IN-THE-TREATMENT-OF-CANCER.html?f=22&fvtc=4&fvtv=9368NEW DATA SUGGESTS IMPROVED TUMOR RESPONSE FOR THE COMBINATION OF AZIXA® AND IMMUNE CHECKPOINT INHIBITORS IN THE TREATMENT OF CANCER2016-06-28T06:30:08Z<![CDATA[
NEW DATA SUGGESTS IMPROVED TUMOR RESPONSE FOR THE COMBINATION OF AZIXA AND
IMMUNE CHECKPOINT INHIBITORS IN THE TREATMENT OF CANCER
Immune Pharmaceuticals Files New Provisional Patent Application
Immune Pharmaceuticals Inc. ("Immune" or the "Company") (NASDAQ:IMNP), a
clinical-stage biopharmaceutical company announced today that recent
preclinical experiments conducted by Dr. Boris Shor, Immunes executive director
of R&D, in collaboration with an independent U.S. based Clinical Research
Organi]]>https://www.globenewswire.com/news-release/2013/11/26/592383/0/en/Immune-Pharmaceuticals-Common-Stock-Approved-for-Trading-on-NASDAQ-OMX-First-North-Premier.html?f=22&fvtc=4&fvtv=9368Immune Pharmaceuticals' Common Stock Approved for Trading on NASDAQ OMX First North Premier2013-11-26T05:38:07Z<![CDATA[TARRYTOWN, N.Y. and HERZLIYA-PITUACH, Israel, Nov. 26, 2013 /PRNewswire/ --
Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP)
announced today that its common stock has been approved for trading on NASDAQ
OMX First North Premier, Stockholm ("First North"). The Company will transfer
its common stock listing from the NASDAQ OMX Stockholm Exchange on November 29,
2013, and the first day of trading on First North will be December 2, 2013.
Erik Penser Bankaktiebolag is eng]]>https://www.globenewswire.com/news-release/2013/11/20/591162/0/en/Immune-Pharmaceuticals-Reports-Third-Quarter-2013-Financial-Results.html?f=22&fvtc=4&fvtv=9368Immune Pharmaceuticals Reports Third Quarter 2013 Financial Results2013-11-20T08:14:07Z<![CDATA[
GAIN ON MERGER TRANSACTION DRIVES INCREASE IN STOCKHOLDERS' EQUITY TO $7.8
MILLION
TARRYTOWN, N.Y. and HERZLIYA-PITUACH, Israel, Nov. 20, 2013 /PRNewswire/ --
Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP)
("Immune" or the "Company") announced today its financial results for the three
and nine month periods ended September 30, 2013. During the third quarter of
2013, Immune recorded net income attributable to common sto]]>https://www.globenewswire.com/news-release/2013/11/01/585717/0/en/Immune-Pharmaceuticals-Appoints-Liquidity-Provider-to-Facilitate-Trading-on-NASDAQ-OMX-Stockholm-Exchange.html?f=22&fvtc=4&fvtv=9368Immune Pharmaceuticals Appoints Liquidity Provider to Facilitate Trading on NASDAQ OMX Stockholm Exchange2013-11-01T06:08:05Z<![CDATA[TARRYTOWN, N.Y. and HERZLIYA-PITUACH, Israel, Nov. 1, 2013 -- Immune
Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) announced
today that it has appointed Erik Penser Bankaktiebolag as a liquidity provider
for the Company's common shares currently listed on NASDAQ OMX Stockholm
Exchange under the trading symbol IMNP. The firm will continue to be the
Company's liquidity provider after its planned transfer of its stock listing
from NASDAQ OMX Stockholm Exchange to NASDAQ OM]]>https://www.globenewswire.com/news-release/2013/10/16/580699/0/en/New-Data-Supports-Clinical-Rationale-for-Bertilimumab-in-Ulcerative-Colitis.html?f=22&fvtc=4&fvtv=9368New Data Supports Clinical Rationale for Bertilimumab in Ulcerative Colitis2013-10-16T04:43:57Z<![CDATA[Phase II Trial to Focus on Moderate to Severe UC Patients with Eotaxin-1
Biomarker
TARRYTOWN, N.Y. and HERZLIYA-PITUACH, Israel, Oct. 16, 2013 /PRNewswire/ --
Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP)
announced today that Tomer Adar, M.D. at the Digestive Diseases Institute,
Shaare Zedek Medical Center, Hebrew University of Jerusalem, presented a poster
on October 15, 2013 entitled Inhibition of Eotaxin-1 (CCL 11) Ameliorates
DSS-Induced Colitis; A Novel]]>https://www.globenewswire.com/news-release/2013/10/15/580335/0/en/Immune-Pharmaceuticals-Announces-Changes-to-its-Board-of-Directors.html?f=22&fvtc=4&fvtv=9368Immune Pharmaceuticals Announces Changes to its Board of Directors2013-10-15T05:04:38Z<![CDATA[New Members Provide strong financing and operating experience
TARRYTOWN, N.Y. and HERZLIYA-PITUACH, Israel, Oct. 15, 2013 /PRNewswire/ --
Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP),
announced today that Rene Lerer, M.D., Executive Chairman of Magellan Health
Services (NASDAQ: MGLN), and Daniel Kazado, Senior Advisor to Melini Capital,
have agreed to join the Company's Board of Directors. Dr. Lerer and Mr. Kazado
replace Pierre Albouy and Herve de Kergrohen]]>https://www.globenewswire.com/news-release/2013/10/03/577780/0/en/IMMUNE-Pharmaceuticals-Inc-to-Present-at-12th-Annual-BIO-Investor-Forum.html?f=22&fvtc=4&fvtv=9368IMMUNE Pharmaceuticals Inc. to Present at 12th Annual BIO Investor Forum2013-10-03T04:37:45Z<![CDATA[TARRYTOWN, N.Y., Oct. 3, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc.
(OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) announced today that Dr. Daniel
G. Teper, Company Chairman and CEO, will be presenting at the 12th Annual BIO
Investor Forum. Hosted by the Biotechnology Industry Organization (BIO), the
12th Annual BIO Investor Forum features leading private and emerging public
companies. The presentation will take place on Wednesday, October 9, 2013 at
10:00 AM local time at the Palace Hote]]>https://www.globenewswire.com/news-release/2013/09/30/576633/0/en/Immune-Pharmaceuticals-Announces-Focus-on-Capital-Raising-and-Primary-Listing-in-The-United-States.html?f=22&fvtc=4&fvtv=9368Immune Pharmaceuticals Announces Focus on Capital Raising and Primary Listing in The United States2013-09-30T07:16:26Z<![CDATA[Company to Transfer Swedish Listing to NASDAQ OMX First North Premier
TARRYTOWN, N.Y., Sept. 30, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc.
(NASDAQ OMX Stockholm Exchange and OTCQX: IMNP) ("IMMUNE" or the "Company")
announced today that following the recent merger of Immune Pharmaceuticals Ltd.
and EpiCept Corporation, the Company will focus its capital raising efforts in
the United States to support its objective to up-list to a U.S. national
securities exchange (NASDAQ or NYSE MKT), w]]>https://www.globenewswire.com/news-release/2013/09/23/574886/0/en/Immune-Pharmaceuticals-Inc-Trading-Symbol-is-Now-IMNP-on-Both-NASDAQ-OMX-Stockholm-Exchange-and-OTCQX-Trading-Platform.html?f=22&fvtc=4&fvtv=9368Immune Pharmaceuticals Inc. Trading Symbol is Now IMNP on Both NASDAQ OMX Stockholm Exchange and OTCQX Trading Platform2013-09-23T04:57:52Z<![CDATA[TARRYTOWN, N.Y., Sept. 23, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc.
(NASDAQ OMX Stockholm Exchange: IMNP and OTCQX: IMNP, formerly EPCTD) announced
today that effective September 23, 2013 the Company's symbol for its common
stock trading on the OTCQX trading platform will change to "IMNP". The
Company's common stock had been required to trade under the symbol "EPCTD"
since August 21, 2013 as a result of the previously implemented 1-for-40
reverse stock split. The Company's common stock h]]>https://www.globenewswire.com/news-release/2013/09/04/571202/0/en/Immune-Pharmaceuticals-Inc-Presenting-At-The-15th-Annual-Rodman-Renshaw-Global-Investment-Conference-In-New-York-City-September-8-10th-2013.html?f=22&fvtc=4&fvtv=9368Immune Pharmaceuticals Inc. Presenting At The 15th Annual Rodman & Renshaw Global Investment Conference In New York City September 8-10th, 20132013-09-04T07:07:33Z<![CDATA[TARRYTOWN, N.Y., Sept. 4, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc.
(NASDAQ OMX Stockholm Exchange: IMNP and OTCQX: EPCTD) today announced it will
be featured as a presenting company at the 15th Annual Rodman & Renshaw Global
Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference
is being held September 8-10, 2013, at the Millennium Broadway Hotel in New
York City.
Daniel Teper, CEO of Immune Pharmaceuticals Inc., will provide an overview of
the Company's busin]]>